Taofeek Owonikoko MD, PhD, MSCR – Lurbinectedin, a potential practice changing drug if approved

Lurbinectedin, a potential practice changing drug if approved, will be the only agent available in SCLC tested with immunotherapy. PharmaMar to submit New Drug Application (NDA) for lurbinectedin under accelerated approval in SCLC in the USA.

lurbinectedin, potential practice changing drug, new drug application (nda), nda, pharmamar, immunotherapy, sclc